Roche Pulls The Plug On PPAR Candidate After Carcinogenicity Tests

Roche will continue to dedicate R&D resources toward the development of diabetes drugs despite the fact the company has decided not to pursue development of R483, its Phase II insulin sensitizer, Pharma CEO William Burns said